Abraham Morgentaler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5231802/publications.pdf

Version: 2024-02-01

93 papers 4,346 citations

32 h-index 65 g-index

94 all docs

94 docs citations

94 times ranked 2986 citing authors

#	Article	IF	CITATIONS
1	Androgen Therapy in Women with Testosterone Insufficiency: Looking Back and Looking Ahead. Androgens: Clinical Research and Therapeutics, 2022, 3, 2-13.	0.2	O
2	Editorial Comment. Journal of Urology, 2022, , 101097JU0000000000238401.	0.2	0
3	Comparison of Patterns of Use and Clinical Outcomes Between Injections of Testosterone Undecanoate and Testosterone Cypionate: An Electronic Health Record Cohort Study. Androgens: Clinical Research and Therapeutics, 2022, 3, 31-40.	0.2	0
4	How the rise of testosterone therapy in men was inspired by lizard research with David Crews. Journal of Experimental Zoology Part A: Ecological and Integrative Physiology, 2022, 337, 103-106.	0.9	1
5	Examining Male Predominance of Severe COVID-19 Outcomes: A Systematic Review. Androgens: Clinical Research and Therapeutics, 2022, 3, 41-53.	0.2	4
6	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Sexual Medicine, 2021, 18, 849-867.	0.3	40
7	Recommendations on the diagnosis, treatment and monitoring of testosterone deficiency in men. Aging Male, 2021, 24, 119-138.	0.9	27
8	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Climacteric, 2021, 24, 533-550.	1.1	4
9	International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women. Journal of Women's Health, 2021, 30, 474-491.	1.5	22
10	Understanding the Controversy Regarding Treatment of Age-Related Testosterone Deficiency. Androgens: Clinical Research and Therapeutics, 2021, 2, 61-63.	0.2	0
11	Testosterone Therapy in Men with Biochemical Recurrence and Metastatic Prostate Cancer: Initial Observations. Androgens: Clinical Research and Therapeutics, 2021, 2, 121-128.	0.2	8
12	Curiosity and other attitudes towards sex robots: Results of an online survey. Journal of Future Robot Life, 2021, , 1-14.	0.5	4
13	The History of Testosterone and the Evolution of its Therapeutic Potential. Sexual Medicine Reviews, 2020, 8, 286-296.	1.5	21
14	Association of low testosterone with changes in non-cardiovascular biomarkers in adult men. International Journal of Impotence Research, 2020, 32, 167-175.	1.0	4
15	A Critique of the AUA Guidelines on Testosterone Deficiency. Journal of Sexual Medicine, 2020, 17, 561-564.	0.3	3
16	Successful treatment of Post-orgasmic illness syndrome with human chorionic gonadotropin. Urology Case Reports, 2020, 29, 101078.	0.1	14
17	Strategies for Testosterone Therapy in Men with Metastatic Prostate Cancer in Clinical Practice: Introducing Modified Bipolar Androgen Therapy. Androgens: Clinical Research and Therapeutics, 2020, 1, 76-84.	0.2	2
18	Interview with Dr. Abraham Morgentaler. Androgens: Clinical Research and Therapeutics, 2020, 1, 3-7.	0.2	0

#	Article	IF	CITATIONS
19	Canadian Urological Association clinical practice guideline on testosterone deficiency in men: Evidence-based Q&A. Canadian Urological Association Journal, 2020, 15, E234-E243.	0.3	8
20	Letter to the editor: Questioning the evidence behind the Saturation Model for testosterone replacement therapy in prostate cancer. Investigative and Clinical Urology, 2020, 61, 452.	1.0	1
21	Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sexual Medicine Reviews, 2019, 7, 95-114.	1.5	5
22	Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine. Sexual Medicine Reviews, 2019, 7, 636-649.	1.5	48
23	Cardiovascular and Cerebrovascular Safety of Testosterone Therapy. American Journal of Medicine, 2019, 132, e748.	0.6	2
24	Safety of testosterone therapy in men with prostate cancer. Expert Opinion on Drug Safety, 2019, 18, 1065-1076.	1.0	11
25	Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth. European Urology Focus, 2019, 5, 81-89.	1.6	17
26	Serum Concentrations of Sex Hormone–binding Globulin Vary Widely in Younger and Older Men: Clinical Data from a Men's Health Practice. European Urology Focus, 2019, 5, 273-279.	1.6	13
27	The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clinical Endocrinology, 2018, 89, 3-10.	1.2	13
28	Do Androgens Modulate the Pathophysiological Pathways of Inflammation? Appraising the Contemporary Evidence. Journal of Clinical Medicine, 2018, 7, 549.	1.0	88
29	Current Diagnostic Criteria for Testosterone Deficiency Are Inadequate. European Urology Focus, 2018, 4, 348-350.	1.6	0
30	Nerve growth factor as a new treatment for testosterone deficiency?. EBioMedicine, 2018, 36, 10-11.	2.7	4
31	Testosterone therapy andÂmedical hysteria. Nature Reviews Urology, 2018, 15, 659-660.	1.9	0
32	Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. European Urology, 2017, 72, 1000-1011.	0.9	163
33	Overselling hysteria. EMBO Reports, 2017, 18, 11-17.	2.0	6
34	The Testosterone Trials: What the Results Mean for Healthcare Providers and for Science. Current Sexual Health Reports, 2017, 9, 290-295.	0.4	0
35	Testosterone Therapy in a Man with Intermediate-risk Prostate Cancer: Pro. European Urology Focus, 2017, 3, 316-318.	1.6	0
36	Initial Clinical Experience With Testosterone Undecanoate Therapy (AVEED) in Men With Testosterone Deficiency in the United States. Urology, 2017, 109, 27-31.	0.5	10

#	Article	IF	CITATIONS
37	Male and Female Sexual Dysfunction in a Rapidly Changing Cultural Environment: Addressing Gender Equality versus Equivalence in the Bedroom. Sexual Medicine Reviews, 2016, 4, 96-102.	1.5	7
38	Testosterone Therapy and Prostate Cancer. Urologic Clinics of North America, 2016, 43, 209-216.	0.8	10
39	Testosterone Therapy Can be Given to Men with No Concern that it will Promote Prostate Cancer Development or Progression. Journal of Urology, 2016, 196, 985-986.	0.2	6
40	Testosterone and cardiovascular disease - what is the story?. Trends in Urology & Men's Health, 2016, 7, 27-29.	0.2	0
41	Controversies and Advances With Testosterone Therapy: A 40-Year Perspective. Urology, 2016, 89, 27-32.	0.5	31
42	Testosterone Therapy in Men With Prostate Cancer. European Urology, 2016, 69, 894-903.	0.9	83
43	Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian Journal of Andrology, 2016, 18, 16.	0.8	64
44	Screening and Monitoring in Men Prescribed Testosterone Therapy in the U.S., 2001–2010. Public Health Reports, 2015, 130, 143-152.	1.3	52
45	Testosterone Therapy after Radiation Therapy for Low, Intermediate and High Risk Prostate Cancer. Journal of Urology, 2015, 194, 1271-1276.	0.2	46
46	Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clinic Proceedings, 2015, 90, 224-251.	1.4	165
47	Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clinic Proceedings, 2015, 90, 1038-1045.	1.4	90
48	Testosterone deficiency and cardiovascular mortality. Asian Journal of Andrology, 2015, 17, 26.	0.8	19
49	The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. Journal of Sexual Medicine, 2015, 12, 1660-1686.	0.3	119
50	Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males. Journal of Hormones, 2014, 2014, 1-17.	0.2	21
51	Testosterone, Cardiovascular Risk, and Hormonophobia. Journal of Sexual Medicine, 2014, 11, 1362-1366.	0.3	27
52	Deaths and Cardiovascular Events in Men Receiving Testosterone. JAMA - Journal of the American Medical Association, 2014, 311, 961.	3.8	21
53	Testosterone and cardiovascular risk: world's experts take unprecedented action to correct misinformation. Aging Male, 2014, 17, 63-65.	0.9	36
54	Does Testosterone Increase the Risk of a Cardiovascular Event?. Journal of Urology, 2014, 192, 13-15.	0.2	7

#	Article	IF	CITATIONS
55	Will I Have a Heart Attack or Stroke If I Take Testosterone Therapy?. Journal of Sexual Medicine, 2014, 11, 1601-1602.	0.3	2
56	Commentary: Who Is a Candidate for Testosterone Therapy? A Synthesis of International Expert Opinions. Journal of Sexual Medicine, 2014, 11, 1636-1645.	0.3	34
57	Factors Influencing Prostate-Specific Antigen Response among Men Treated with Testosterone Therapy for 6 Months. Journal of Sexual Medicine, 2014, 11, 2818-2825.	0.3	36
58	Reply to Julia Klap and Kevin R. Loughlin's Letter to the Editor re: Mohit Khera, David Crawford, Alvaro Morales, Andrea Salonia, Abraham Morgentaler. A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications. Eur Urol 2014;65:115–23. European Urology, 2014, 66, e33.	0.9	0
59	Bone Mineral Density and Response to Treatment in Men Younger Than 50 Years with Testosterone Deficiency and Sexual Dysfunction or Infertility. Journal of Urology, 2014, 191, 1072-1076.	0.2	33
60	Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical Considerations. Journal of Urology, 2013, 189, S26-33.	0.2	37
61	Testosterone Therapy in Men With Untreated Prostate Cancer. Journal of Urology, 2011, 185, 1256-1261.	0.2	134
62	Re: Adverse Events Associated With Testosterone Administration. European Urology, 2011, 59, 465.	0.9	8
63	Should Hypogonadal Men With Prostate Cancer Receive Testosterone?. Journal of Urology, 2010, 184, 1257-1260.	0.2	5
64	Rapidly Shifting Concepts Regarding Androgens and Prostate Cancer. Scientific World Journal, The, 2009, 9, 685-690.	0.8	11
65	ORIGINAL RESEARCH—ENDOCRINOLOGY: Two Years of Testosterone Therapy Associated with Decline in Prostate-Specific Antigen in a Man with Untreated Prostate Cancer. Journal of Sexual Medicine, 2009, 6, 574-577.	0.3	30
66	Testosterone Deficiency and Peyronie's Disease: Pilot Data Suggesting a Significant Relationship. Journal of Sexual Medicine, 2009, 6, 1729-1735.	0.3	50
67	Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. European Urology, 2009, 55, 310-321.	0.9	376
68	Testosterone Therapy in Men With Prostate Cancer: Scientific and Ethical Considerations. Journal of Urology, 2009, 181, 972-979.	0.2	41
69	Re: Effect of Testosterone Supplementation on Functional Mobility, Cognition, and Other Parameters in Older Men: A Randomized Controlled Trial. European Urology, 2008, 53, 1084.	0.9	3
70	Guilt by Association: A Historical Perspective on Huggins, Testosterone Therapy, and Prostate Cancer. Journal of Sexual Medicine, 2008, 5, 1834-1840.	0.3	31
71	Long Acting Testosterone Undecanoate Therapy in Men With Hypogonadism: Results of a Pharmacokinetic Clinical Study. Journal of Urology, 2008, 180, 2307-2313.	0.2	46
72	Guideline for Male Testosterone Therapy: A Clinician's Perspective. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 416-417.	1.8	32

#	Article	IF	CITATIONS
73	Testosterone Replacement Therapy and Prostate Cancer. Urologic Clinics of North America, 2007, 34, 555-563.	0.8	72
74	Controversies in Sexual Medicine: Penile Rehabilitation Should Become the Norm for Radical Prostatectomy Patients. Journal of Sexual Medicine, 2007, 4, 538-543.	0.3	97
75	Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology, 2006, 68, 1263-1267.	0.5	200
76	ORIGINAL RESEARCHâ€"ED PHARMACOTHERAPY: Efficacy and Safety of Tadalafil Across Ethnic Groups and Various Risk Factors in Men with Erectile Dysfunction: Use of a Novel Noninferiority Study Design. Journal of Sexual Medicine, 2006, 3, 492-503.	0.3	25
77	ORIGINAL RESEARCHâ€"ENDOCRINOLOGY: Wide Variability in Laboratory Reference Values for Serum Testosterone. Journal of Sexual Medicine, 2006, 3, 1085-1089.	0.3	61
78	Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. European Urology, 2006, 50, 935-939.	0.9	219
79	Testosterone replacement therapy and prostate risks: where's the beef?. Canadian Journal of Urology, 2006, 13 Suppl 1, 40-3.	0.0	5
80	Risks of Testosterone-Replacement Therapy and Recommendations for Monitoring. New England Journal of Medicine, 2004, 350, 482-492.	13.9	650
81	Testosterone Replacement Therapy in Hypogonadal Men at High Risk for Prostate Cancer: Results of 1 Year of Treatment in Men With Prostatic Intraepithelial Neoplasia. Journal of Urology, 2003, 170, 2348-2351.	0.2	173
82	Quality-of-life after penile prosthesis placed at radical prostatectomy. Psychology and Health, 2000, 15, 651-661.	1.2	6
83	Pathologic Features of Occult Prostatic Carcinoma in Hypogonadal Men. Prostate Journal, 2000, 2, 74-79.	0.2	3
84	PARTIAL DUPLICATION OF THE VAS DEFERENS. Journal of Urology, 1998, 159, 988-989.	0.2	12
85	Experimental Cryptorchidism Induces Testicular Germ Cell Apoptosis by p53-Dependent and -Independent Pathways In Mice. Biology of Reproduction, 1998, 58, 492-496.	1.2	136
86	Temperature-Mediated Germ Cell Loss in the Testis is Associated With Altered Expression of the Cell-Cycle Regulator p53. Journal of Urology, 1997, 157, 1986-1989.	0.2	33
87	Occult Prostate Cancer in Men With Low Serum Testosterone Levels. JAMA - Journal of the American Medical Association, 1996, 276, 1904.	3.8	192
88	Spontaneous Corporeal Herniation of the Penis: A New Abnormality of the Tunica Albuginea?. Journal of Urology, 1995, 153, 737-740.	0.2	4
89	Re: Unilateral Unitary Inflatable Penile Prosthesis to Correct Impaired Tumescence and Severe Penile Deformity Resulting from Traumatic Rupture of 1 Corpus Cavernosum. Journal of Urology, 1995, 154, 1145-1145.	0.2	2
90	A Self-Expanding Prostatic Stent for Bladder Outlet Obstruction in High Risk Patients. Journal of Urology, 1993, 150, 1636-1640.	0.2	14

#	Article	IF	CITATIONS
91	Rapid high resolution two-dimensional electrophoresis of human sperm proteins. Electrophoresis, 1992, 13, 445-449.	1.3	10
92	Management of the Impacted Ureteral Calculus. Journal of Urology, 1990, 143, 263-266.	0.2	127
93	EFFECTS OF INTRACRANIAL IMPLANTATION OF OESTRADIOL AND DIHYDROTESTOSTERONE ON THE SEXUAL BEHAVIOUR OF THE LIZARD ANOLIS CAROLINENSIS. Journal of Endocrinology, 1979, 82, 373-381.	1.2	46